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STUDY PROTOCOL Open Access
Intravenous iron isomaltoside versus oral
iron supplementation for treatment of iron
deficiency in pregnancy: protocol for a
randomised, comparative, open-label trial
Veronika Markova1,2,3* , Rebecka Hansen1,4, Lars Lykke Thomsen2,3, Anja Pinborg5, Torben Moos3 and
Charlotte Holm1
Abstract
Background: Iron deficiency is common in pregnancy. If left untreated, iron deficiency can lead to iron deficiency
anaemia, which is a condition related to maternal and neonatal morbidity. The prevalence of iron deficiency
increases through the trimesters, which means that women with iron deficiency in the beginning of pregnancy also
have a great risk of developing iron deficiency anaemia during pregnancy. Standard treatment is oral iron in
individualised intensified doses based on screening values in 1st trimester.
Maternal symptoms of iron deficiency and iron deficiency anaemia include fatigue, reduced physical performance,
and restless legs syndrome (RLS). Severe anaemia may cause dizziness, dyspnea, palpitation, orthostatism, and
syncope, and it decreases the woman’s ability to cope with blood loss during delivery. The anaemia may also
compromise contractility in the uterine musculature increasing the risk for prolonged labour, caesarean section, and
postpartum haemorrhage. Foetal iron deficiency may cause low birthweight and adversely affect foetal and early
childhood brain development with long-term deficits.
Methods: In this randomised comparative, open-label, single-centre, phase IV trial, 200 pregnant women between
14 and 21 weeks of gestation who have iron deficiency after 4 weeks of standard treatment will be randomised 1:1
to either a single 1000 mg dose of intravenously administered ferric derisomaltose/iron isomaltoside 1000 or a fixed
dose of 100 mg oral ferrous fumarate containing 60 mg ascorbic acid.
The primary endpoint is to prevent iron deficiency anaemia defined by a low level of haemoglobin throughout the
trial. Other endpoints include other haematological indices of iron deficiency and anaemia, clinical outcomes by
questionnaires, and collection of adverse events. Explorative endpoints by medical record follow-up include
complications up to 7 days after delivery.
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Discussion: This trial will provide evidence on how to prevent iron deficiency anaemia. The trial population represents
a clinical reality where pregnant women often have sustained iron deficiency despite an increased oral iron dose. Thus,
this evidence can be used to consider the optimal 2nd line of treatment in iron-deficient pregnant women.
Trial registration: European Union Drug Regulating Authorities Clinical Trials Database 2017-000776-29. Registered on
3 May 2017.
ClinicalTrials.gov NCT03188445. Registered on 15 June 2017.
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Introduction
Background and rationale {6a}
Untreated iron deficiency (ID) in pregnancy can lead to
iron deficiency anaemia (IDA) [1, 2]. ID in pregnancy is
defined by low iron stores, measured by a level of
circulating ferritin < 30 μg/L [3–6]. Iron is essential for
basic cellular processes, such as cell division and the
synthesis of haemoglobin (Hb) [7]. Anaemia in pregnancy
is defined by a Hb level < 11.0 g/dL, WHO [1, 5]. Thus,
IDA in pregnancy is defined as Hb < 11.0 g/dL and serum-
(s)-ferritin < 30 g/μg/L.
In Danish pregnant women, who do not take iron
supplementation, approximately 50% have ID and 21%
have IDA [8]. Anaemia (regardless the cause) is
estimated to occur in 24% of Danish pregnant women
(WHO).
The prevalence of ID is approximately 7% in 1st
trimester, 14–40% in 2nd trimester, and 30–62% in 3rd
trimester [9, 10]. Prevalence of IDA is approximately 2%
in 1st trimester, 8% in 2nd trimester and, 27% in 3rd
trimester [11, 12]. The steep increase in ID and IDA
through the trimesters illustrates that women with ID in
the beginning of pregnancy have a great risk of
developing IDA during pregnancy.
National recommendations on routine iron
supplementation in pregnancy do not necessarily prevent ID
and IDA as seen in a Swizz study, where approximately 32%
of pregnant women in 2nd trimester had ID and 6.2% IDA
despite a recommended daily oral iron dose of 80mg [13].
Maternal symptoms of ID and IDA include fatigue/
exhaustion, reduced physical performance, restless legs
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syndrome (RLS), and decreased ability to cope with
blood loss during delivery. Severe anaemia may cause
dizziness, shortness of breath, palpitation, orthostatism,
and syncope [14, 15]. Iron is an essential part of
myoglobin, which explains why ID may compromise
contractility in the uterine musculature that in turn may
increase the risk for prolonged labour, caesarean section,
and postpartum haemorrhage [16, 17]. The consequence
of maternal anaemia for the foetus is low birthweight,
which can complicate the neonatal period [18–21]. ID
during foetal life may adversely affect brain development
with long-term deficits. One trial showed that maternal
anaemia in pregnancy could be linked to 14% of cases of
mental retardation at a 7-year follow-up [22].
Thus, isolated ID can be symptomatic and adversely
affect foetal brain development. ID is a precursor for
IDA, which is associated with maternal and foetal/
neonatal morbidity. If treated early in pregnancy, the
consequences of ID can be prevented.
In clinical practice, the standard treatment of ID and
IDA in pregnancy recommended by the Danish Society
of Obstetricians and Gynaecologists (DSOG) is oral iron
supplementation in individualised doses based on
screening values of Hb and ferritin in 1st trimester [23].
Oral iron supplementation is associated with
gastrointestinal adverse effects, affecting patient compliance
[14]. Thus, not all women treated with oral iron will respond
to or comply with treatment. The recommendations are not
clear on how to act in case of failure of the standard
treatment. Thus, a pregnant woman with sustained ID will
most likely be recommended to remain on oral iron and
only receive intravenous (IV) iron if she becomes anaemic.
However, it has not yet been investigated what treatment—
intensified oral iron or IV iron—is most favourable in case
the recommended standard treatment is not sufficient.
Treatment with intravenous ferric derisomaltose/iron
isomaltoside 1000 (FDI) (Monofer®/Monoferric®,
Pharmacosmos, Holbaek) is indicated when oral
treatment is ineffective and when rapid iron delivery is
clinically indicated. FDI is one of the newer IV iron
formulations available. It was initially launched in Europe
in 2010 and consists of iron and a carbohydrate moiety
where the iron is tightly bound in a matrix structure. It is
the matrix structure that enables a controlled and slow
release of iron to iron-binding proteins, avoiding potential
toxicity from release of labile iron [24]. FDI has been stud-
ied in non-clinical reprotoxicology trials. In supra thera-
peutic doses, foetal malformations were seen in rabbits
[Monofer® Investigators Brochure]. The risk for terato-
genic or foeto-toxic effects is considered minimal at the
proposed therapeutic dose. Several studies of FDI treat-
ment of iron deficiency anaemia have been published
without detected unexpected safety issues [25–31]. FDI
should be confined to second and third trimester if the
benefit is judged to outweigh the potential risk for both
the mother and the foetus [6, 32, 33].
Ferrous fumarate containing ascorbic acid denotes a
combination product administered in a film-coated tab-
let for oral ingestion. Ferrous fumarate is a ferrous salt.
Ascorbic acid (vitamin C) facilitates iron uptake by
maintaining iron in its ferrous form [34, 35].
Previous trials have investigated the use of different IV
iron preparations in pregnant women with IDA [36–42].
We have not been able to identify trials investigating the
use of IV iron for prevention of IDA in iron-deficient
pregnant women. A recent trial where pregnant women
with IDA were treated with the IV iron formulation fer-
ric carboxymaltose reported a statistically significant im-
provement in Hb change from baseline in the IV iron
group compared to oral iron group at 6 weeks. Overall
hypersensitivity reactions were rare, IV iron treatment
had a beneficial effect on Hb increase, and neonatal out-
comes did not differ between groups [40].
There are several reasons why it is important to
systematically investigate if the use of IV iron is an
effective and attractive mode of treatment in pregnancy
compared to intensified oral iron treatment in women
with sustained ID despite standard treatment: ID rarely
resolves despite standard treatment, is unlikely to
resolve later in pregnancy if still present after 4 weeks of
standard care, is often left untreated in cases of
intolerance to oral iron, is unfavourable for the foetus,
and can progress into severe ID and IDA in later
trimesters.
Therefore, measures to effectively treat ID early to
prevent IDA are of great clinical importance.
Objectives {7}
In order to prevent IDA throughout the trial in pregnant
women, who have ID after 4 weeks of standard treatment,
the primary objective is to compare the efficacy of a single
dose of IV administered FDI with a fixed dose of oral
ferrous fumarate containing ascorbic acid.
The secondary objectives are to compare the effect of
IV FDI and oral ferrous fumarate with ascorbic acid on
(i) haematological indices of IDA in maternal blood, (ii)
maternal fatigue and quality of life (QoL), (iii) RLS, (iv)
the need for an additional IV FDI dose or (rescue) red
blood cell (RBC) transfusion, and (v) safety.
Trial design {8}
The trial is a randomised, comparative, open-label,
single-centre, phase IV trial, with planned 200 women
randomised 1:1 to a single dose of IV FDI or a fixed
dose of oral iron ferrous fumarate with ascorbic acid.
The randomisation is stratified by Hb value (≥ or <
11.0 g/dL).
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Methods: participants, interventions, and
outcomes
Study setting {9}
The trial is being conducted at the Department of
Obstetrics and Gynecology at Copenhagen University
Hospital, Amager-Hvidovre Hospital, which is a tertiary
hospital with 7000–8000 yearly deliveries.
Healthy women who wish to participate and fulfil the
inclusion criteria are enrolled at gestational age (GA)
14 + 0–21 + 0. The duration for each participant is
approximately 18 weeks and involves four follow-up
visits by a trial investigator at the Amager-Hvidovre
Hospital.
Eligibility criteria {10}
Pregnant women at GA 14 + 0–21 + 0 are eligible for
inclusion if they fulfil the following criteria: s-ferritin <
30 μg/L (0–29 μg/L) after 4 weeks of standard treatment,
age ≥ 18 years, and signed informed consent form.
The exclusion criteria are as follows: multiple
pregnancies; history of anaemia not caused by iron
deficiency; iron overload or disturbances in utilisation of
iron; previous hypersensitivity to IV iron or to any
excipients in the investigational drug products; active
asthma within the last 5 years; multiple allergies; known
decompensated liver cirrhosis or active hepatitis; active
acute or chronic infections (assessed by clinical
judgement); rheumatoid arthritis with symptoms or
signs of active inflammation; treated with IV iron
products, blood transfusion, or erythropoietin within 4
weeks prior to inclusion; participation in any other
interventional trial where the trial drug has not passed 5
half-lives prior to inclusion; any other medical condition
that, in the opinion of the investigator, may cause the
participant to be unsuitable for the completion of the
trial or place the participant at potential risk from being
in the trial; meeting RBC transfusion criteria (Hb ≤ 6.9
g/dL = ≤ 4.3 mmol/L with intolerable symptoms of an-
aemia or an Hb ≤ 6.4 g/dL (≤ 4.0 mmol/L) regardless of
anaemia symptoms; and inability to read and understand
the Danish language.
Who will take informed consent? {26a}
Trial investigators will obtain informed consent.
Additional consent provisions for collection and use of
participant data and biological specimens {26b}
On the consent form, the participants will be informed
about the use and storage of personal data collected
during their participation in the trial, i.e. until
completion of trial or withdrawal of consent, this in
accordance with the General Data Protection Regulation
(GDPR). The consent form contains information
concerning the personnel who can access personal data
collected during this trial, i.e. investigators, monitor, and
regulatory authorities.
By signing the informed consent form, the participants
agree to the terms addressed in the form.
This trial involves collecting biological specimens for
storage.
Interventions
Explanation for the choice of comparators {6b}
The choice of the comparator is based on current
standard treatment of ID in pregnancy.
Intervention description {11a}
A. IV FDI administered at the baseline visit as a single
dose of 1000 mg (if pre-pregnancy body weight <
50 kg then 20mg/kg pre-pregnancy body weight).
The dose is diluted in 100 ml 0.9% sodium chloride
and is given over approximately 20 min.
B. Fixed dose oral ferrous fumarate (100 mg elemental
iron) with ascorbic acid 60 mg [34], once daily.
Criteria for discontinuing or modifying allocated
interventions {11b}
If the participant has IDA at T6w or T12w defined as Hb
< 11 g/dL and s-ferritin < 30 μg/L, an additional dose of
IV iron isomaltoside is allowed in both groups (not at
T18w due to lack of AE monitoring). The maximum
cumulative dose is set to 2000 mg for the individual
participant.
Strategies to improve adherence to interventions {11c}
Compliance to oral treatment is encouraged at every
follow-up visit.
Relevant concomitant care permitted or prohibited
during the trial {11d}
Iron supplementation other than study treatment is
prohibited.
Provisions for post-trial care {30}
There is no anticipated harm and compensation for trial
participation. Post-trial, the pregnant women will be
cared for in a clinical setting, i.e. standard antenatal care,
where both intervention and comparator therapies are
available.
Outcomes {12}
The primary endpoint of this trial is a Hb ≥11.0 g/dL (≥
6.8 mmol/L) at all trial visits post-baseline (T3w, T6w,
T12w, and T18w).
The secondary endpoints are Hb ≥ 11.0 g/dL (≥ 6.8
mmol/L) at each follow-up visit, change in Hb and other
haematological indices of ID/IDA from baseline to each
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follow-up visit (e.g. reticulocytes, reticulocyte haemoglo-
bin content (CHr), s-ferritin, s-transferrin, s-iron, hepci-
din, and calculated transferrin saturation (TSAT)),
incidence of hypophosphatemia (defined as serum [s]-
phosphate < 2 mg/dL) from baseline to each follow-up
visit, change in fatigue and quality of life questionnaires
from baseline to each follow-up visit, presence of RLS at
each follow-up visit, number of participants who receive
an additional IV iron isomaltoside dose at T6w and/or
T12w, reason for the additional IV iron isomaltoside dose
(non-compliance, lack of effect), number of participants
receiving RBC transfusions and the number of RBC
units per transfused participant from baseline to final
subject visit, type and incidence of AEs observed at any
time until final subject visit, serious or severe hypersen-
sitivity reaction starting at or after the first dose of ran-
domised treatment, AEs of special interest (constipation,
diarrhoea, flatulence, nausea, vomiting, abdominal pain,
dyspepsia, dysgeusia, and stool discoloration), number of
participants who discontinue from the trial because of
lack of response or intolerance of investigational drugs,
foetal bradycardia related to infusion of IV iron isomal-
toside at or after GA 26, change in biochemical safety
parameters from baseline to each follow-up visit, and
compliance to treatment: at baseline in the IV group and
at T6w and T18w in the oral group.
Specific explorative endpoints registered between final
subject visit up until 7 days postpartum will be extracted
from medical records: incidence of maternal antepartum
haemorrhage, thromboembolic events, gestational diabetes
mellitus, gestational hypertensive disorders, blood
transfusions, prolonged labour, length of labour, oxytocin
use, assisted delivery, unplanned caesarean section,
postpartum haemorrhage, maternal blood loss at labour (ml),
length of maternal and neonatal hospital admission,
maternal death, incidence of intrauterine growth retardation,
preterm birth, ante- or postnatal asphyxia, low birthweight,
neonatal infection, neonatal anaemia, required paediatric
assistance, admission to neonatal ward, congenital
malformations, foetal or neonatal death, GA at delivery, date
of delivery and birthweight.
Clinical outcome measures
The FACIT-fatigue questionnaire has been validated in a
mixed population of patients with IDA. The
questionnaire consists of 13 items regarding fatigue.
Each item has a response scale of 0–4, 0 being ‘not at
all’ and 4 being ‘very much so’. The score for each item
is added up to a summed score, where a low score
equals more fatigue and higher score equals a better
condition. Selected items are there for reversed when
adding up the total score.
The Short Form 12 (SF-12) is used to evaluate quality
of life (QoL). The SF-12 is derived from the more
comprehensive SF-36. Both SF-12 and SF-36 cover the
two summary measures of physical and mental health
through eight domains/scales (physical functioning,
physical role, bodily pain, general health, vitality, social
function, emotional role, mental health) which in turn
are covered by 12 items. Higher scores indicate better
conditions.
RLS is evaluated by using the four diagnostic criteria
[43] as a quantitative outcome which is either present or
not present.
Participant timeline {13}
The participants will attend the baseline visit and 4
follow-up visits: T3w 3 weeks (± 2 days), T6w 6 weeks (±
3 days), T12w 12 weeks (± 1 week), and T18w 18 weeks (±
1 week) from baseline (see Figs. 1 and 2).
Sample size {14}
The sample size calculations are based on the primary
endpoint: Hb ≥ 11 g/dL (≥ 6.8 mmol/L) at all time points
after baseline [1, 5]. The primary endpoint will be
estimated by a Kaplan-Meier curve. Participants who
drop out during the trial will be accounted for (set as
‘censored’) by the methodology and therefore not ad-
dressed specifically in the sample size calculations. It is
assumed that 5% and 17.5% of the participants in the
FDI and oral treatment groups respectively will have a
Hb < 11 g/dL at some point during the trial, correspond-
ing to 95% and 82.5% will have a Hb ≥ 11 g/dL at all
post-baseline visits. Using a significance level of 5%, and
setting the power to 80%, 100 participants in each treat-
ment group are required in order to detect the assumed
difference between FDI and oral iron.
Recruitment {15}
The women will be recruited from the clinical setting.
Standard clinical procedures for pregnant women at the
trial site include 1st trimester screening for iron
deficiency and anaemia by measuring Hb and serum
ferritin. Women with ID or IDA are recommended
intensified oral iron supplementation and repeated blood
samples in the 2nd trimester. Women with persistent
iron deficiency despite this standard oral treatment are
contacted, informed about the trial, and are invited to
the baseline visit.
Assignment of interventions: allocation
Sequence generation {16a}
The procedure for preparing the randomisation list is
approved by the Global Trial Responsible Statistician.
The randomisation list is prepared by BioStata ApS,
Birkeroed, Denmark.
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Concealment mechanism {16b}
The allocation list is imputed in the electronic Case
Report File (eCRF) and lies prepared within the eCRF.
The sequence list is not accessible to the investigators.
Implementation {16c}
The investigators consecutively invited all eligible
participants to attend the baseline visit. At the baseline
visit, demographics and latest Hb level are entered in the
eCRF prior to randomisation. Thereafter, the participant
is randomised stratified by Hb value and proceeds to the
allocated treatment.
Assignment of interventions: blinding
Who will be blinded {17a}
This trial is open label. Neither the outcome assessors
nor data analysts are blinded.
Procedure for unblinding if needed {17b}
The design is open label so unblinding will not occur.
Data collection and management
Plans for assessment and collection of outcomes {18a}
Data is collected during the five trial visits and by
medical record follow-up. Source data is defined as all
information in original records or certified copies of ori-
ginal records of clinical findings, observations, or other
activities in a clinical trial necessary for reconstruction
and evaluation of the trial. Source data is entered from
paper source into an eCRF.
Laboratory analysis data is drawn electronically from
the hospitals IT system to the eCRF.
Plans to promote participant retention and complete
follow-up {18b}
The participant has the right to withdraw from the trial
at any time and for any reason without prejudice to her
future medical care by the physician or at the institution.
If a participant withdraws from the trial, the investigator
will perform all final visit assessments besides the
scheduled trial assessments for that visit.
Fig. 1 Illustration of trial flow (SF-12, Short Form 12; FACIT-fatigue, questionnaire on fatigue; AEs, adverse events; IDA, iron deficiency anaemia)
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Fig. 2 Schedule for enrolment, intervention, and assessment during the trial
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As part of the subject information, the purpose of the
trial and the importance of completing the trial will be
explained to the subjects. Subject compliance (oral iron
group) will be followed throughout the trial and advices
and guidelines provided in case of non-compliance. Both
treatment groups will be in regular contact with the
investigator.
In extraordinary/force major situations, the principal
investigator can temporarily suspend trial visits, e.g. if
entering the hospital carries a risk for the participant. In
such case, we will attempt to collect information via
telephone or email, where possible, and schedule trial-
related laboratory analyses simultaneously with any pre-
scheduled appointments in a clinical setting. The au-
thorities will be informed promptly in case of such tem-
porary restructuring actions, including the reason for the
decision.
Data management {19}
Data management is outsourced. The data collection
tool for this trial is the eCRF, which is compliant with
21 CFR Part 11 regulations. Clinical data management is
performed in accordance with applicable standards and
data cleaning procedures.
Confidentiality {27}
Data are handled confidentially and stored in a locked
archive.
Plans for collection, laboratory evaluation, and storage of
biological specimens for genetic or molecular analysis in
this trial/future use {33}
Blood samples will be collected by venous puncture at
every participant visit. Haematological indices of ID/IDA
as well as safety indices will be analysed within hours
and evaluated by the investigators during the next
working day at the latest. A single tube containing
plasma from each visit will be stored at the trial site and
will be used to assess hepcidin at an external laboratory.
The samples will be destroyed after analysis or latest at
completion of the trial. Thus, specimens collected at
trial visits will not be used for genetic analyses or
analyses in any future trials.
Statistical methods
Statistical methods for primary and secondary outcomes
{20a}
Time to Hb < 11 g/dL and proportion of participants
with correction of anaemia (Hb ≥ 11.0 g/dL) at T3w, T6w,
and T12w will be estimated by a Kaplan-Meier curve
using scheduled visits. Based on the Kaplan-Meier curve,
the proportion of participants who have met the primary
endpoint (achievement/maintenance of Hb ≥ 11 g/dL at
all post-baseline visits) at T18w will be estimated and
compared between the treatment groups.
The primary endpoint analysis will be performed for
the intention-to-treat analysis set and will be repeated
for the full analysis set and per protocol analysis sets.
As sensitivity, the risk difference will be used to
compare the proportion of participants with Hb ≥ 11 g/
dL at all post-baseline visits. Risk difference and the as-
sociated 95% Newcombe CI and p value will be calcu-
lated, adjusting for strata (Hb </≥ 11 g/dL at inclusion)
using the Cochran-Mantel-Haenszel method. In this
analysis, participants who do not complete the study
period will be set as failures.
The change in Hb and biochemical safety parameters
from baseline to T3w, T6w, T12w, and T18w will be
analysed using a restricted maximum likelihood-based
mixed model for repeated measures approach.
The proportion of participants who (a) receive an
additional IV FDI dose, (b) receive allogenic RBC
transfusions, (c) discontinue from the trial because of
lack of response or intolerance of investigational drugs,
and (d) develop hypophosphatemia will be compared
between the treatment groups by Fisher’s exact test.
The number of units of RBC transfused per transfused
participant from baseline to final subject visit will be
compared between the treatment groups by an analysis
of variance or Wilcoxon test.
For participants in the oral iron group, AEs with onset
at/after the time of first additional IV iron isomaltoside
dose will be excluded from the main AE summaries. In
addition, displays of all AEs per overall treatment group
will be produced, as well as summaries and participant
listings of AEs occurring at/after the time of first
additional IV iron isomaltoside dose.
Medical record follow-up will be tabulated by descrip-
tive statistics.
Interim analyses {21b}
No interim analyses are planned. The trial sponsor and
the principal investigator can temporarily suspend or
prematurely discontinue the trial at any time for reasons
such as safety, ethical issues, severe non-compliance, and
insufficient subject enrolment. The authorities will be in-
formed promptly in case of suspension or termination,
including the reason for the decision.
Methods for additional analyses (e.g. subgroup analyses)
{20b}
No additional analyses are planned.
Methods in analysis to handle protocol non-adherence
and any statistical methods to handle missing data {20c}
The intention-to-treat (ITT) analysis set will include all
subjects as randomised. The per protocol (PP) analysis
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set will include all subjects who do not have any major
protocol or GCP deviation of clinical or statistical sig-
nificance. Non-compliance, i.e. treatment dose outside
the 80–120% range within the first 6 weeks of treatment,
is considered a major protocol deviation.
All participants in the intention-to-treat analysis set
with post-baseline Hb data will be included with their
observed data. Participants without post-baseline Hb
values will have change from baseline set to 0 at the first
post-baseline visit. The model will include the fixed, cat-
egorical effects of treatment, week, and treatment-by-
week interaction as well as the continuous, fixed covari-
ates of baseline Hb value and baseline Hb-by-week inter-
action. Similar analyses will be performed for the other
haematological indices (reticulocytes etc.), change in fa-
tigue, QoL, and RLS.
Plans to give access to the full protocol, participant level-
data, and statistical code {31c}
The protocol, individual subject data, and statistical
codes will not be available. The primary and secondary
endpoints will be uploaded to EudraCT in accordance
with national requirements.
Oversight and monitoring
Composition of the coordinating centre and trial steering
committee {5d}
Pharmacosmos sponsors the trial and the responsibility for
the quality and integrity of the trial data resides with
Pharmacosmos. Pharmacosmos has a Quality Management
System in place to ensure that the trial is conducted, and
data are generated, documented (recorded), and reported in
compliance with the protocol, International Conference on
Harmonization-Good Clinical Practice (ICH-GCP), and the
applicable regulatory requirements. The oversight of data
quality will be provided by a trial core team who consist of
personnel responsible for project management, medical
monitoring, statistics, data management, medical writing,
GCP quality control, and GCP quality assurance. The re-
sponsibility of the trial core team is to ensure high data
quality, regulatory compliance, scientific validity, and trans-
parency in all activities in the clinical trial via robust planning
and timely action. The trial core team will meet regularly to
follow-up on the trial progress. Monitoring, data manage-
ment, and statistics is handled by Vendors, but the ultimate
responsibility for the quality and integrity of the trial data al-
ways resides with Pharmacosmos.
All trial-specific monitoring information and proce-
dures are described and controlled via a monitoring
guideline and a project plan. All monitoring reports are
reviewed and approved by the Pharmacosmos project
director. A risk management plan ensures ongoing risk
assessment and adequate mitigation throughout the trial.
The investigator is responsible for trial execution at
site including enrolment of trial subjects and collecting
informed consent. Subjects receive both written and oral
information about the trial, and they are giving time for
consideration and questions before providing written
consent. The consent procedure for each subject is
checked as part of the Source Data Review/Source Data
Verification as part of the monitoring procedure.
Composition of the data monitoring committee, its role
and reporting structure {21a}
There will not be selected a data monitoring committee.
Instead, the oversight of data quality will be provided by a
trial core team. Roles and responsibilities of the trial core
team are described in section 5d—the “Composition of
the coordinating centre and trial steering committee”
section.
Adverse event reporting and harms {22}
AEs are collected and evaluated for relatedness to trial
drug, seriousness, severity, expectedness, and outcome.
AE are defined in the ICH-GCP guideline.
Frequency and plans for auditing trial conduct {23}
To ensure compliance with ICH-GCP guidelines and all
applicable regulatory requirements, Pharmacosmos A/S,
its designee, or its regulatory agencies may conduct a
regulatory inspection of this trial, in which case direct
access to all source data and documents is mandatory.
Plans for communicating important protocol
amendments to relevant parties (e.g. trial participants,
ethical committees) {25}
Protocol amendments will be submitted to the Ethical
Committee and Danish Medicines Agency and
implemented after approval.
Dissemination plans {31a}
The results of the trial, positive as well as negative, will
be published by the end of the trial. Also, the findings of
this trial will be presented as part of a PhD thesis and
defence.
The primary endpoint and key secondary endpoints
(AEs and change in Hb, serum ferritin, and TSAT from
baseline to T3w, T6w, T12w, and T18w) will be uploaded
on public websites according to national requirements.
Discussion
The objective of this study is to compare IV FDI to oral
iron therapy for the prevention of IDA in iron-deficient
pregnant women.
We use the first-choice treatment method as a com-
parator in our trial. Therefore, we will be able to use the
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study results for assessing the potential benefit of IV FDI
in a clinical setting.
In the first approved version of our protocol, we
aimed to recruit women with IDA. However, we soon
discovered that IDA is rare in 1st and beginning of 2nd
trimester in Danish women. Thus, to recruit pregnant
women with IDA, we either would have to examine
women in 3rd trimester or prepare for a very long
enrolment period (i.e. a decade). At this point, it became
clear that a preventive approach would be beneficial for
both the pregnant women and for the progression of our
trial. This resulted in a trial design aiming to prevent
IDA, as opposed to treating IDA after manifestation. It
is well known that IDA causes morbidity [14–22].
However, previous studies have focused on treatment
[36–42]. We have focused on prevention, thereby
minimising the damage that IDA can cause before
effectively treated. From a clinical perspective, it makes
good sense to avoid the development of morbidity rather
than treating it, once occurred. IV iron treatment is
more expensive than oral treatment, both because of the
cost of the actual medicine, but also costs associated
with administration. However, IV iron might correct ID
faster and have higher compliance than oral treatment
and thereby reduce complications at delivery (i.e. length
of hospital admission, surgery, RBC transfusions),
making this a highly relevant trial in a socioeconomic
context as well.
This trial stands out from other trials regarding the
rather strict policy on the gestational age time window
for the five trial visits, which we consider a great
strength in our study design. We thereby acknowledge
that pregnancy is a state with major haemodynamic,
hormonal, and physiological changes. We know that
haemoglobin drops in 2nd/3rd trimester as part of a
physiological process which prepares the pregnant
woman for the blood loss associated with delivery [44].
Also, pregnancy symptoms such as fatigue and nausea
are more common in 1st trimester and tend to subside
in 2nd trimester [45, 46]. By recruiting pregnant women
who are all at approximately the same GA at inclusion
and thereby also at the follow-up visits, we ensure that
the participants are at the same physiological stages at
the respective visits. We hypothesise that this will make
both the laboratory and clinical result more homoge-
neous between the treatment groups in that all data is
equally affected by the physiological deviations during a
pregnancy.
We consider the evaluation of clinically relevant
outcomes as a strength in our trial, as these outcomes
are very important to investigate. Optimally, we would
have used a tool that has been validated in this specific
population (European iron-deficient/anaemic pregnant
women), which could detect differences in symptoms of
ID/IDA while accounting for pregnancy. However, such
a tool that fulfils all these criteria does not exist. A re-
cent review illustrates how sparse clinical outcome
reporting generally is in trials on perinatal IDA [47].
We chose two self-administered questionnaires in the
official Danish versions: FACIT-fatigue and SF-12 in
their unedited form (copyright protected). Permission to
use the questionnaires has been obtained from the offi-
cial websites. Both questionnaires are validated in a
broader population. This is a limitation in our trial.
We chose the FACIT-fatigue questionnaire because
fatigue is considered the most common symptom of
anaemia. The questionnaire contains questions that
seem appropriate for a pregnant woman and is simple,
short, and manageable.
For evaluation of QoL, we chose the 12-question ver-
sion, rather than the 36-question version, because we
did not want to risk the combined body of questionnaire
material to cause drop out due to an overwhelming
amount of questions at each visit. The SF-12 question-
naire addresses emotional wellbeing as part of quality of
life assessment. This aspect of ID/IDA is of increasing
interest, e.g. a recent study in women after postpartum
haemorrhage showed that postpartum depression scores
(Edinburgh Postnatal Depression Scale) improved sig-
nificantly in the intravenous iron group compared to the
standard treatment group [30].
The evaluation of RLS is based on four diagnostic
questions, rather than using an available rather
comprehensive questionnaire, which was a deliberate
choice on our part to keep the combined body of
questionnaire material to a manageable level.
As a habitually low Hb and a mild/moderate ID is
often asymptomatic, the differences in clinical outcomes
of ID/IDA can be difficult to detect. We therefore chose
Hb for the primary outcome in this trial.
Trial status
The first protocol version (P-Monofer-PREG-01 version
1) was approved on 7 April 2017.
The first participant was randomised on 11 December
2017. The final participant was randomised on 28
February 2020, thus approximately 2 months after the
initial submission of this manuscript.
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